Pros | ![]() Lower expense ratio. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 3Y returns in the bottom 25% of the category. | - |
INDMoney rank | 6/8 | 5/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 2691 Cr | 8352 Cr | ||
Min Investment | SIP ₹99 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.5% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.41%) Divi's Laboratories Ltd (7.65%) Aurobindo Pharma Ltd (6.98%) Cipla Ltd (6.23%) Apollo Hospitals Enterprise Ltd (5.76%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.64%) Basic Materials (1.36%) | Health (100%) | ||
Equity % | 99.36% | 98.58% | ||
Debt % | - | - | ||
P/E | 36.02 | 36.85 | ||
P/B | 5.05 | 5.96 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.9% | 2.76% | ||
3-Month Return | 4.43% | 7.71% | ||
6-Month Return | -2.2% | 0.03% | ||
1-Year Return | 19.21% | 18.05% | ||
3-Year Return | 25.35% | 26.73% | ||
5-Year Return | 23.59% | 23.19% |
Sharpe | 0.94 | 1.13 | ||
Alpha | -1.37 | 1.66 | ||
Beta | 1 | 0.9 | ||
Standard Deviation | 16.52 | 14.97 | ||
Information Ratio | -0.61 | 0.02 |
Description | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Vrijesh Kasera | Sailesh Raj Bhan,Kinjal Desai |